Clinical Trial: The efficacy and safety of irinotecan hydrochloride liposome injection (II) combined with apatinib mesylate tablets in the second-line treatment of locally advanced or metastatic HER-2 negative gastric or gastroesophageal junction adenocarcinoma: A single-arm, prospective, exploratory clinical study (China)

China, Aug. 24 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'The efficacy and safety of irinotecan hydrochloride liposome injection (II) combined with apatinib mesylate tablets in the second-line treatment of locally advanced or metastatic HER-2 negative gastric or gastroesophageal junction adenocarcinoma: A single-arm, prospective, exploratory clinical study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130688

Registration Time: 2026/08/23

Type: Interventional study

Primary Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=323960 ...